healthcare policy
Discussion and Debate
Multinational Pharmaceutical Companies Shortchange Canada in Research and Development Investments: Is It Time to Pursue Other Options?
Shoo K. Lee, Sukhy K. Mahl, Jessica J. Green and Joel Lexchin
Discussion and Debate
Commentary: Reconsidering Pharmaceutical Research and Development Investments
Marc-André Gagnon
Research Paper
Nursing Home Residents’ Use of Radiography in New Brunswick: A Case for Mobile Radiography?
Eric Plant, Rose McCloskey, Isdore Chola Shamputa, Kavish Chandra, Paul Atkinson, Jacqueline Fraser,...
Invited Paper
Expensive Drugs for Rare Diseases in Canada: What Value and At What Cost?
Sandra Sirrs, Helen Anderson, Bashir Jiwani, Larry D. Lynd, Eric Lun, Bob Nakagawa, Dean Regier, Shi...
Commentary
Expensive Drug Prices for Rare Cancers: Are Patients Truly Benefitting?
Kristina Jenei and Bishal Gyawali
Commentary
Can Managed Access Agreements Mitigate Evidentiary, Economic and Ethical Issues with Access to Expensive Drugs for Rare Diseases in the Canadian Context?
Melanie McPhail and Tania Bubela
The Authors Respond
Expensive Drugs for Rare Diseases in Canada: Time for Action Everywhere and by Everyone
Sandra Sirrs, Helen Anderson, Bashir Jiwani, Eric Lun, Bob Nakagawa, Dean Regier, Shirin Rizzardo an...